• 1
    Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 6657.
  • 2
    Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002; 25: 17397.
  • 3
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 256371.
  • 4
    Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-α antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30: 23158.
  • 5
    Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44: 15763.
  • 6
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 7
    Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 57: 94566.
  • 8
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 134159.
  • 9
    Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor-α inhibitor. Eur J Haematol 2003; 71: 3968.
  • 10
    Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 153843.
  • 11
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64 Suppl 4: iv214.
  • 12
    Montane E, Salles M, Barriocanal A, Riera E, Costa J, Tena X. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007; 26: 15279.
  • 13
    Rajakulendran S, Gadsby K, Allen D, O'Reilly S, Deighton C. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis [letter]. Ann Rheum Dis 2006; 65: 16789.
  • 14
    Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept [letter]. Rheumatology (Oxford) 2008; 47: 3767.
  • 15
    Yazdani R, Simpson H, Kaushik V. Incidence of cytopoenias in anti-TNF-α therapy [abstract]. Rheumatology (Oxford) 2007; 46: i33.
  • 16
    National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (final appraisal determination). 2006. URL:
  • 17
    Rajakulendran S, Allen D, Deighton C. Should the monitoring of methotrexate and leflunomide be the same? [abstract]. Rheumatology (Oxford) 2005; 44: i65.
  • 18
    Lim AY, Gaffney K, Scott DG. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford) 2005; 44: 10515.
  • 19
    Hashimoto Y, Ziff M, Hurd ER. Increased endothelial cell adherence, aggregation, and superoxide generation by neutrophils incubated in systemic lupus erythematosus and Felty's syndrome sera. Arthritis Rheum 1982; 25: 140918.
  • 20
    Breedveld FC, Lafeber GJ, de Vries E, van Krieken JH, Cats A. Immune complexes and the pathogenesis of neutropenia in Felty's syndrome. Ann Rheum Dis 1986; 45: 696702.
  • 21
    Gamberale R, Giordano M, Trevani AS, Andonegui G, Geffner JR. Modulation of human neutrophil apoptosis by immune complexes. J Immunol 1998; 161: 366674.
  • 22
    Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999; 57: 1621.
  • 23
    Keystone EC. Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 42743.
  • 24
    Cross A, Moots RJ, Edwards SW. The dual effects of TNFα on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood 2008; 111: 87884.
  • 25
    Cross A, Bakstad D, Allen JC, Thomas L, Moots RJ, Edwards SW. Neutrophil gene expression in rheumatoid arthritis. Pathophysiology 2005; 12: 191202.